Feeds
Bristol-Myers Squibb Co. is splitting off its holdings in infant formula maker Mead Johnson Nutrition Co. in order to focus on its biopharmaceutical business.
Bristol-Myers Squibb Co. and Alder Biopharmaceuticals Inc. said Tuesday they signed a collaboration deal potentially worth $1 billion, with a key focus on a rheumatoid arthritis treatment.
Bristol-Myers Squibb Co., the world's No. 15 drug maker by revenue, reports earnings for the third quarter on Thursday morning. The following is a summary of key developments and analyst opinion related to the period.
Federal health regulators on Friday approved a potential blockbuster diabetes drug from Bristol-Myers Squibb Co. and partner Astrazeneca PLC.
A federal panel said Wednesday a diabetes drug from Bristol-Myers Squibb appears free from heart problems seen with similar drugs but added that long-term studies should be done after approval to confirm its safety.
A potential blockbuster diabetes medication from Bristol-Myers Squibb appears free from heart-related side effects that have plagued similar treatments, federal health officials said Monday.
Drugmaker Bristol-Myers Squibb said Tuesday it will eliminate another 10 percent of its work force through 2010 as it works to pare costs before it loses patent protection on key drugs.
Eli Lilly and Co. and Bristol-Myers Squibb both beat earnings expectations and posted 14 percent third-quarter revenue gains Thursday, while the market responded with healthy increases for their stocks.
The state of Alabama has settled Medicaid drug pricing lawsuits it filed against prescription drug manufacturer Bristol-Myers Squibb and four other companies, a lawyer representing the state confirmed Friday.
Eli Lilly & Co.'s winning bid of more than $6 billion for cancer drugmaker ImClone Systems means a billion-dollar payday for former rival bidder Bristol-Myers and vindication for corporate raider and ImClone Chairman Carl Icahn.
Bristol-Myers Squibb Co. might be willing to drop its quest to acquire partner biotech company ImClone Systems Inc. — under unspecified conditions.
Bristol-Myers Squibb Co. on Thursday offered $4.5 billion in cash for its cancer drug partner, biotechnology company ImClone Systems Inc., saying the two are "a natural fit."
First Pfizer, then Merck, now Bristol-Myers Squibb plans to cut jobs as the pharmaceutical industry wrestles with profits being siphoned off to generic drugs.
Pharmaceuticals maker Bristol-Myers Squibb Co. announced a major restructuring plan that includes a 10 percent work force reduction, the shuttering of more than half of its manufacturing plants and a significant cutback in its mature product offerings.
Drug developer Bristol-Myers Squibb Co. said Thursday its third-quarter profit more than doubled on a surge in sales of its blood thinner Plavix, and raised its outlook for adjusted 2007 earnings.
Pharmaceutical Company Executive in Drugs for Sex and Sex for Studies ScandalFormer AstraZeneca U.S.
Log In | Register
